story of the week
Participatory Role of Inflammation in Atherosclerotic Disease Confirmed by CANTOS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- ESC 2017: The Interleukin-1β Inhibitor Canakinumab Cuts Cardiovascular Disease and Lung Cancer Risk by Reducing Inflammation - CANTOS Trial
- Dr. Clyde Yancy Contextualizes Key Trials From ESC 2017
- 2017 Top Stories in Cardiology: The Inflammation Hypothesis of Atherosclerosis Comes of Age: The CANTOS Trial
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Antiinflammatory Therapy With Canakinumab for Atherosclerotic Disease
N. Engl. J. Med 2017 Aug 27;[EPub Ahead of Print], PM Ridker, BM Everett, T Thuren, JG MacFadyen, WH Chang, C Ballantyne, F Fonseca, J Nicolau, W Koenig, SD Anker, JJP Kastelein, JH Cornel, P Pais, D Pella, J Genest, R Cifkova, A Lorenzatti, T Forster, Z Kobalava, L Vida-Simiti, M Flather, H Shimokawa, H Ogawa, M Dellborg, PRF Rossi, RPT Troquay, P Libby, RJ GlynnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.